Open access
Open access
Powered by Google Translator Translator

Oncology – Lung

RCT | Efficacy and safety of carboplatin with nab-paclitaxel vs. docetaxel in older patients with squamous non-small-cell lung cancer.

14 Sep, 2022 | 13:00h | UTC

Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial – The Lancet Health Longevity

 

Commentary on Twitter

 


RCT | Dexamethasone is not effective for the treatment of dyspnea in patients with cancer and increases the risk of adverse events.

13 Sep, 2022 | 13:22h | UTC

Effect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial – The Lancet Oncology (free for a limited period)

 

Commentary on Twitter

 


RCT | Anatomical segmentectomy vs. standard lobectomy for non-small cell lung cancer up to 2 cm.

6 Sep, 2022 | 14:28h | UTC

Survival outcomes in a prospective randomized multicenter Phase III trial comparing patients undergoing anatomical segmentectomy versus standard lobectomy for non-small cell lung cancer up to 2 cm – Lung Cancer

Related:

A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation.

Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial – The Lancet (link to abstract – $ for full-text)

A Meta-Analysis Comparing Lobectomy versus Segmentectomy in Stage I Non-Small Cell Lung Cancer – The Korean Journal of Thoracic and Cardiovascular Surgery

 


RCT | Cemiplimab plus chemotherapy vs. chemotherapy alone in non-small cell lung cancer.

29 Aug, 2022 | 12:08h | UTC

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial – Nature Medicine

 

Commentary on Twitter

 


RCT | Nivolumab vs. nivolumab plus docetaxel for previously treated advanced or recurrent immune checkpoint inhibitor-naïve non-small-cell lung cancer.

25 Aug, 2022 | 11:48h | UTC

A randomized comparison of nivolumab versus nivolumab + docetaxel for previously treated advanced or recurrent ICI-naïve non-small-cell lung cancer: TORG1630 – Clinical Cancer Research

 


M-A | Erlotinib plus bevacizumab vs. erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer.

22 Aug, 2022 | 12:04h | UTC

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials – BMJ Open

 


RCT | Chest CT scan plus x-ray vs. chest x-ray for the follow-up of completely resected non-small-cell lung cancer.

16 Aug, 2022 | 13:50h | UTC

Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter (thread – click for more)

 


Long-term results of a RCT | Gefitinib-alone vs. Gefitinib plus chemotherapy for non–small-cell lung cancer with mutated EGFR.

15 Aug, 2022 | 11:44h | UTC

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR – Journal of Clinical Oncology

Original Study: Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study – Journal of Clinical Oncology

 


RCT | Palliative radiation for advanced central lung tumors with intentional avoidance of the esophagus.

9 Aug, 2022 | 12:24h | UTC

Palliative Radiation for Advanced Central Lung Tumors With Intentional Avoidance of the Esophagus (PROACTIVE): A Phase 3 Randomized Clinical Trial – JAMA Oncology

Commentary: Esophagus-Sparing Radiation Fails QOL Test in Lung Cancer— Esophageal-specific quality of life no better, but treatment reduced symptomatic esophagitis – MedPage Today (free registration required)

 

Commentary on Twitter

 


Systematic Review | Impact of low‐dose computed tomography screening on lung cancer‐related mortality.

8 Aug, 2022 | 11:52h | UTC

Impact of low‐dose computed tomography (LDCT) screening on lung cancer‐related mortality – Cochrane Library

Summary: Impact of computed tomography (CT) on lung cancer screening – Cochrane Library

Related:

Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study – The BMJ

Screening for Lung Cancer: CHEST Guideline and Expert Panel Report.

USPSTF Statement: begin screening for lung cancer at age 50 years instead of 55 years for patients at risk

Meta-analysis: Lung cancer screening using low-dose computed tomography reduces lung cancer–specific mortality, albeit with a tradeoff of likely overdiagnosis

 


RCT | Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy.

3 Aug, 2022 | 14:02h | UTC

Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


M-A | Lung cancer occurrence after an episode of tuberculosis.

29 Jul, 2022 | 12:28h | UTC

Lung cancer occurrence after an episode of tuberculosis: a systematic review and meta-analysis – European Respiratory Review

 


Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer.

22 Jul, 2022 | 11:07h | UTC

Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer – European Respiratory Review

 


A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation.

15 Jul, 2022 | 12:55h | UTC

A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation – Journal of Thoracic Disease

Part 1 – A guide to decision-making

Part 2 – Systematic review of evidence regarding resection extent in generally healthy patients

Part 3 – Systematic review of evidence regarding surgery in compromised patients or specific tumors

Part 4 – Systematic review of evidence involving SBRT and ablation

 


ASCO Living Guideline | Therapy for stage IV non–small-cell lung cancer with driver alterations.

12 Jul, 2022 | 12:46h | UTC

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline – Journal of Clinical Oncology

 

Commentary on Twitter

 


ASCO Living Guideline | Therapy for stage IV non–small-cell lung cancer without driver alterations.

12 Jul, 2022 | 12:44h | UTC

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline – Journal of Clinical Oncology

 

Commentary on Twitter

 


Cohort Study | Association of high tumor mutation burden in non–small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels.

11 Jul, 2022 | 11:53h | UTC

Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels – JAMA Oncology

Author Interview: High TMB in NSCLC and Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade – JAMA

Commentaries:

Tumor mutational burden ‘valuable biomarker’ for ICI response in NSCLC – medwire News

Tumor Mutational Burden Associated With Responses, Immune Cell Infiltration in NSCLC – Cancer Network

 

Commentary on Twitter

 


Guideline | Malignancy risk stratification for solitary pulmonary nodule.

4 Jul, 2022 | 12:33h | UTC

Malignancy risk stratification for solitary pulmonary nodule: A clinical practice guideline – Journal of Evidence-Based Medicine


Single-arm phase II study: EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma.

24 Jun, 2022 | 10:49h | UTC

EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)

 


RCT: Furmonertinib vs. gefitinib as first-line therapy for patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer.

9 Jun, 2022 | 10:25h | UTC

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study – The Lancet Respiratory Medicine (link to abstract – $ for full-text)

 


#ASCO22 – Phase 2 single-arm study: Adagrasib in non–small-cell lung cancer harboring a KRASG12C mutation.

6 Jun, 2022 | 11:15h | UTC

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Targeted drug achieves 43% response rate in KRAS-mutated lung cancer – Dana-Farber Cancer Institute

 


#ASCO22 – Phase II RCT: Ramucirumab and pembrolizumab vs. standard of care in advanced non–small-cell lung cancer previously treated with immunotherapy.

6 Jun, 2022 | 11:14h | UTC

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A – Journal of Clinical Oncology

Commentary: New drug combination lengthened survival for some with lung cancer – SWOG Cancer Research Network

 

Commentary on Twitter

 


Summary of best evidence for enhanced recovery after surgery for patients undergoing lung cancer operations.

3 Jun, 2022 | 11:02h | UTC

Summary of best evidence for enhanced recovery after surgery for patients undergoing lung cancer operations – Asia-Pacific Journal of Oncology Nursing

Related:

Guidelines for enhanced recovery after lung surgery: recommendations of the Enhanced Recovery After Surgery (ERAS®) Society and the European Society of Thoracic Surgeons (ESTS) – European Journal of Cardio-Thoracic Surgery

Enhanced recovery programs in lung cancer surgery: systematic review and meta-analysis of randomized controlled trials – Cancer Management and Research

Clinical guidelines on perioperative management strategies for enhanced recovery after lung surgery – Translational Lung Cancer Research

Systematic Review and Meta-Analysis of Randomized, Controlled Trials on Preoperative Physical Exercise Interventions in Patients with Non-Small-Cell Lung Cancer – Cancers

Preoperative exercise training for patients with non‐small cell lung cancer – Cochrane Library

 


Cardiac metastasis from solid cancers: a 35-year single-center autopsy study.

3 Jun, 2022 | 10:54h | UTC

Cardiac Metastasis From Solid Cancers: A 35-Year Single-Center Autopsy Study – Archives of Pathology & Laboratory Medicine

 


M-A: Stereotactic radiosurgery vs. whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer.

30 May, 2022 | 10:41h | UTC

Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis – The Lancet Oncology (link to abstract – $ for full-text)

News Release: Meta-Analysis Shows Targeted Radiation Therapy May Be as Effective as Standard Care for Small Cell Lung Cancer Patients with Brain Metastases – St. Michael’s Hospital

 


Stay Updated in Your Specialty

No spam, just news.